Kidney transplantation is the treatment of choice for chronic end-stage renal disease, offering greater survival when compared to dialysis. 1 The gap between the number of patients and available organs has been steadily increasing. 2 Currently there is no international consensus on the factors that should be considered in the kidney allocation process. The major debate in the allocation of scarce donor organs centers on the competing ethical values of utility (maximum outcomes) and equity (fairness). 3 The current Portuguese criteria for allocation include criteria to satisfy both these principles: candidates' waiting time on dialysis and state of hypersensitization for fairness; and maximization of human leukocyte antigen (HLA) compatibility, and age differential between donor and recipient for utility. When this allocation system was introduced, in 2007, one of its main objectives was to mitigate the disadvantage of hypersensitized patients who were subjected to disproportionately longer waiting times. 4 Ten years later, it is now time to evaluate its outcomes and introduce changes for improvement in light of new clinical data.
Research such as the article "Donor-recipient pair selection in renal transplantation: comparative results from a simulation" 5 published in this edition of Acta Médica Portuguesa, constitutes an invaluable landmark for future deliberations. This article results from years of investigation led by the authors and has the merit of simulating the application of a new allocation model. 3 In the authors' proposal organs are distributed among four groups of candidates stratified by time on dialysis and hypersensitization status. Each group is assigned a color: red (clinical urgency), orange (calculated panel reactive antibody (cPRA) ≥ 85% or dialysis time greater than the 3 rd quartile, i.e. dialysis time required until 75% of the candidates on the waiting list are transplanted), yellow (cPRA ≥ 50% or with a dialysis time greater than the median of dialysis time required until transplantation), and lastly, green (encompassing the remaining candidates). In this proposal clinical urgency is the top priority. While many allocation systems do not include medical urgency as a criteria, it seems important to recognize that not all patients can afford to wait the same amount of time. 3 The proposed color priority system improves transparency by rendering allocation more intelligible to patients, and addresses one of the most criticized aspects of current allocation systems: waiting time on dialysis as the primary driver of allocation. 6 The authors' results suggest that the mere reduction of the scoring currently attributed to dialysis time (0.1 points per month) may be insufficient to produce appreciable benefits. Another positive change proposed is the definition of hypersensitization according to calculated panel reactive antibody (PRA) cPRA, instead of PRA by complement-dependent cytotoxicity. The later method unfairly disadvantages hypersensitized candidates, by increasing their waiting time unduly. 7 Use of cPRA for allocation purposes has already been successfully implemented in other countries. 8 Having based their simulation on data concerning only HLA genotype distribution of the Portuguese northern population, the authors recognize that it is only possible to estimate the likelihood of obtaining a compatible organ for a specific recipient if national HLA data is available, which is still not the current practice. 9 In the near future HLA matching is expected to be determined at the epitope level. This will allow identification of more suitably mismatched donors for non-sensitized patients, as well as, acceptable mismatches for sensitized transplant candidates. 10 Nonetheless, there is a general trend toward a reduction in the influence of HLA mismatch and an increase in the importance of other factors shown to affect the longevity mismatch of organs and recipients. 3 The new allocation system introduced in the United States (USA) in 2014 allows for a reasonable estimation of recipient's survival and graft longevity, and preferentially allocates kidneys with longer expected duration of function to patients expected to live longer. 11 In the USA, prediction of graft survival was shown to be significantly improved when considering donor comorbidities (hypertension, diabetes, etc) in addition to age alone. 11, 12 In their simulation the authors propose an old-to-old allocation, similar to that implemented by Eurotransplant, which has presented satisfactory results. 13 Allocation systems are subject to permanent reform worldwide. Other options currently being discussed include use of hepatitis C virus infected donors, and marginal grafts with a favorable pathology examination. 14, 15 Some countries have also opted to give priority to patients who have previously donated a kidney. 16 Countries with geographic size similar to Portugal, such as Israel, have opted to allocate organs only at a national level, without any local or regional priority. In allocation systems where this has been implemented, access for disadvantaged patient groups has improved, especially for hypersensitized patients. 17 However, national shipping of kidneys may create logistical challenges and may increase cold ischemic time, and delayed graft function, as seen in the United States. 6, 17 Other strategies to expand the donor pool have consisted on the use of kidneys retrieved after cardiac death. This that was been legally established in 2013 has yet to achieve its full potential, with only a limited number of transplant centers currently performing it.
The implementation of new measures regarding kidney allocation will necessarily affect the current balance between efficiency and fair access. Therefore vigilant monitoring and critical assessment of the outcomes will be necessary from the kidney transplant community as potential consequences could include reduction in transplant rates for specific patient groups. 18 Despite their inherent limitations, simulations remain the best method to predict future changes.
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